Received Jul 10, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 1 | 77D52 | IM |
adjuvant was given without being mixed with the active ingredient; adjuvant was given without being mixed with the active ingredient; This non-serious case was reported by a other health professional and described the occurrence of inappropriate preparation of medication in a 52-year-old male patient who received Herpes zoster (Shingrix) (batch number 77D52, expiry date 16-SEP-2025) for prophylaxis. On 13-FEB-2025, the patient received the 1st dose of Shingrix (intramuscular). On 13-FEB-2025, an unknown time after receiving Shingrix, the patient experienced inappropriate preparation of medication (Verbatim: adjuvant was given without being mixed with the active ingredient) and inappropriate dose of vaccine administered (Verbatim: adjuvant was given without being mixed with the active ingredient). The outcome of the inappropriate preparation of medication and inappropriate dose of vaccine administered were not applicable. Additional Information: GSK Receipt Date: 26-JUN-2025 Reporter state that only adjuvant was given without being mixed with the active ingredient, which led to inappropriate preparation of medication and inappropriate dose of vaccine administered. This case is linked with case US2025061270, reported by the same reporter.; Sender's Comments: US-GSK-US2025061270:Same reporter/Different patient